A team of AIDS researchers, including two Harvard biostatisticians, published an article in the Journal of the American Medical Association last week detailing the failures of an HIV vaccine, despite the protests of the study's sponsor.
The sponsor, Immune Response, filed a lawsuit in September for seven to ten million dollars immediately following the research team's refusal to include the company analysis of the study's results.
The suit specifically names the research team leader, James Kahn, a professor from the University of California at San Francisco (UCSF), and the UCSF regents.
While the firm maintains it should have a role in shaping the study's analysis, the scientists--whose findings indicated the HIV vaccine was a dud--said scientific freedom was their guiding principle.
Kahn headed the study along with Dr. Kenneth Mayer, an AIDS researcher at Brown, and two Harvard biostatisticians, Professor of Biostatistics Stephen Lagakos and Deborah Weng Cheng, a biostatistician in the Center for Biostatistics in AIDS Research.
Immune Response, a California-based biotech company, commissioned the study in 1995 to use 2,500 HIV patients as a test study for the HIV vaccine, Remune.
They tested the ability of Remune to boost the immune response of HIV-infected people by reducing the patient's viral load because "it showed some activity in the lab," Cheng said.
However, by May 1999 the patients receiving Remune in addition to standard HIV treatment were faring no better than the control group, causing the Data Safety Monitoring Board and Immune Response to agree to stop the study, Kahn said.
Upon presentation of their paper describing Remune's ineffectiveness, Kahn says it was clear they "did not present an analysis that the sponsor wanted."
"They wanted the right to review all manuscripts," Kahn said of Immune Response, which the researchers refused because it was "clear it was a way to delay publication."
Dr. Ronald B. Moss, vice president of medical and scientific affairs for Immune Response, refused to comment. Calls to the public relations office were not returned.
Both Kahn and Cheng stressed their duty to the patients who participated in the Remune study in publishing their negative data.
"Patients involved in research treatment should be involved with the outcome," Cheng said.
For the researchers, the Immune Response lawsuit endangers the larger issue of scientific freedom and places a conditional value on scientific research.
"They're sort of like bullies in a sandbox--they take their toys and escape," Kahn said of Immune Response.
But the scientists said they are not concerned about the future of scientific research.
"So far my colleagues have been very supportive," Kahn says, "I just hope that people will not wait for sanitized results."
Lagakos is currently in Japan and could not be reached for comment.
Thursday, June 30, 2011
Immune Response BioPharma
The people at Immune Response BioPharma have sent a letter to the FDA trying to get approval of the Remune vaccine developed by Immune Response aka Orchestra. In the letter they refer to the people at Immune Response by saying, "while the former management was unethical and irresponsible and cared only about their wallets and stock price." This is a true statement. Thousands of honest investors lost all their money due to the false statements and research conducted by Kevin Kimberlin's and Spencer Trask's company. My question is why would the FDA approve anything based on the research results provided by people who were "unethical and irresponsible." I mean lying to investors and trying to manipulate lap test results were what Immune Response was known for. The FDA and future investors would be fools to trust any of the Immune Response's research data. If they believe in the science they are going to have to start from scratch and repeat everything with reputable scientists and doctors administering the clinical trials and then allow for independent peer review from their fellow professionals in the field.
Wednesday, June 29, 2011
Immune Response class action lawsuit
Immune Response was known for releasing misleading reports about their research results and their chances for approval. This finally resulted in a lawsuit. Despite the suit almost all the investors in Immune Response lost their investment.
CARLSBAD, Calif., Nov. 14 /PRNewswire-FirstCall/ -- The Immune Response Corporation (BULLETIN BOARD: IMNR) announced today that the Company has reached an agreement with class counsel to settle the consolidated federal securities law class action litigation filed against the Company in 2001, as well as the related California state-court derivative lawsuit, without admitting to any wrongdoing, fault or liability. The settlements also include Company directors and officers who were named in the lawsuits.
The class action settlement, for approximately $9.6 million, will have no effect on the Company's operations, cash flow or financial position, as it is within insurance limits. The settlement is conditioned on notice to the class members and court approval. The preliminary settlement approval hearing is scheduled to occur on December 4, 2006.
The shareholder derivative complaint was filed on July 5, 2005 against certain of the Company's current and former officers and directors. The Company was also named as a nominal defendant in the complaint.
The $0.25 million settlement for the California state-court derivative lawsuit would also be funded entirely by the Company's insurers. As anticipated by an agreement in principle for the settlement, the Company will also agree to adopt certain corporate governance requirements. The definitive state-court settlement agreement is conditioned on court approval and must be filed with the court by November 20, 2006. The settlement hearing is scheduled to occur on November 27, 2006.
About The Immune Response Corporation
The Immune Response Corporation (BULLETIN BOARD: IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of multiple sclerosis (MS) and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
IR103 is based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of Remune(R), the Company's first generation HIV product candidate. The federal class action litigation was based on the Company's reporting of results from one of those clinical studies of Remune(R). IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time.
CARLSBAD, Calif., Nov. 14 /PRNewswire-FirstCall/ -- The Immune Response Corporation (BULLETIN BOARD: IMNR) announced today that the Company has reached an agreement with class counsel to settle the consolidated federal securities law class action litigation filed against the Company in 2001, as well as the related California state-court derivative lawsuit, without admitting to any wrongdoing, fault or liability. The settlements also include Company directors and officers who were named in the lawsuits.
The class action settlement, for approximately $9.6 million, will have no effect on the Company's operations, cash flow or financial position, as it is within insurance limits. The settlement is conditioned on notice to the class members and court approval. The preliminary settlement approval hearing is scheduled to occur on December 4, 2006.
The shareholder derivative complaint was filed on July 5, 2005 against certain of the Company's current and former officers and directors. The Company was also named as a nominal defendant in the complaint.
The $0.25 million settlement for the California state-court derivative lawsuit would also be funded entirely by the Company's insurers. As anticipated by an agreement in principle for the settlement, the Company will also agree to adopt certain corporate governance requirements. The definitive state-court settlement agreement is conditioned on court approval and must be filed with the court by November 20, 2006. The settlement hearing is scheduled to occur on November 27, 2006.
About The Immune Response Corporation
The Immune Response Corporation (BULLETIN BOARD: IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of multiple sclerosis (MS) and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide vaccine technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
IR103 is based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of Remune(R), the Company's first generation HIV product candidate. The federal class action litigation was based on the Company's reporting of results from one of those clinical studies of Remune(R). IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time.
Monday, June 27, 2011
Immune Response Test Results
The following article appeared Nov. 7, 2000 concerning research results from Immune Response.
Sunday, June 26, 2011
Orchestra
I am keeping this blog in an attempt to make people aware of the connection between Immune Response Corp. and Orchestra Thera and Immune Response BioPharma and to hopefully bring attention to the FTC and major financial and investment publications of what happened to the investors who financed the research that David Buswell and Immune Response BioPharma are now trying to market. I also would like to discover if there is a connection between Immune Response BioPharma and Kevin Kimberlin and Spencer Trask and if what Immune Response BioPharma is attempting to do is legal and morally fair to the investors of Immune Response/Orchestra.
Thursday, June 23, 2011
Kevin Kimberlin
I finally received a response back from an Eric Swanson at Immune Response Biophrma. He said the following:
"Per your note to Mr. Buswell, it's my understanding you have issues relating to his medical and business efforts. While I'm not a brankruptcy expert, I believe the science he has embraced was abandoned by the parties you mentioned in your email. It seems to me he's trying to make good on something that was left to the trash collectors."
He also went on to say,
"it is my understanding accredited investors will perhaps have an opportunity to participate in an Immune Response Biopharma Private Offering or Initial Public Offering of shares."
The company's website says,
"Dividends: The Company plans to pay regular dividends Annual $1.00 per share dividend beginning on December 25th 2011, and quarterly dividends of $.25c per share on March 30th 2012, June 30th 2012, September 30th 2012, and December 25th 2012.
Partnering out manufacturing and drug development the company intends to become a royalty generating income producing company."
I guess I am confused. Immune Reponse/Orchestra could not get anyone to partner with them nor invest in the company nor could they obtain any grant money to help stay in business. The entire scientific community said the company's test trails were fatally flawed and that their approach was outdated and basically a waste of time. The stock price dropped to below a penny a share and the company had to file Chapter 7 due to lack of funding and investment.
Now this Buswell comes along and as Stewart says he pulls the research papers from Immune Response/Orchestra out of the trash barrel and now he's going to form a new company, start paying dividends, partner with other companies and go public with an IPO for accredited investors only.
Is he running a con on ignorant investors or did Kevin Kimberlin and Spencer Trask con the rest of the investors in Immune Response/Orchestra out of their money and property rights?
Where is Buswell getting his financing from? Could it be Kevin Kimberlin and Spencer Trask or behind him?
"Per your note to Mr. Buswell, it's my understanding you have issues relating to his medical and business efforts. While I'm not a brankruptcy expert, I believe the science he has embraced was abandoned by the parties you mentioned in your email. It seems to me he's trying to make good on something that was left to the trash collectors."
He also went on to say,
"it is my understanding accredited investors will perhaps have an opportunity to participate in an Immune Response Biopharma Private Offering or Initial Public Offering of shares."
The company's website says,
"Dividends: The Company plans to pay regular dividends Annual $1.00 per share dividend beginning on December 25th 2011, and quarterly dividends of $.25c per share on March 30th 2012, June 30th 2012, September 30th 2012, and December 25th 2012.
Partnering out manufacturing and drug development the company intends to become a royalty generating income producing company."
I guess I am confused. Immune Reponse/Orchestra could not get anyone to partner with them nor invest in the company nor could they obtain any grant money to help stay in business. The entire scientific community said the company's test trails were fatally flawed and that their approach was outdated and basically a waste of time. The stock price dropped to below a penny a share and the company had to file Chapter 7 due to lack of funding and investment.
Now this Buswell comes along and as Stewart says he pulls the research papers from Immune Response/Orchestra out of the trash barrel and now he's going to form a new company, start paying dividends, partner with other companies and go public with an IPO for accredited investors only.
Is he running a con on ignorant investors or did Kevin Kimberlin and Spencer Trask con the rest of the investors in Immune Response/Orchestra out of their money and property rights?
Where is Buswell getting his financing from? Could it be Kevin Kimberlin and Spencer Trask or behind him?
Tuesday, June 21, 2011
David Buswell and Immune Response
The following was a third response I received from the compnay after contacting them and asking if they planned on compensating the investors in Immune Response and Orchestra who financed the research Immune Response BioPharma is attempting to market.
RE: Cease & Desist Order Multiple Violations
You have violated the Cease & Desist order twice, i am afraid you will have to be blocked from Microsoft and your IP domain address is being reported to the proper authorities, and multiple criminal complaints lodged against you with state and federal agencies for repeated violations of the rule of law, please get necessary help mental and counseling and medication to help you with your illegal activities, this will not be tolerated and the courst system will be notified of your harrassment, and illegal activities including the, DOJ, FBI, U.S. Postal Inspector, North Carolina State Police and Statesville, NC Local Police for your blackmailing, extortion, and attempting to obtaint money and securities under false pretences violations of federal and state laws, while this is unfortunate Immune Response BioPharma is forced to protect itself from financial terrorisim you have victimized our new company from. I demand you obey the Cease & Desist Order from 2/24/2011 and obey the rule of law and cease your criminal activities. Immune Response BioPharma will use and seek all available avenues of civil and criminal law to end your blackmailing and extortion attempts.
Sincerely,
Immune Resonse BioPharma Legal Department
RE: Cease & Desist Order Multiple Violations
You have violated the Cease & Desist order twice, i am afraid you will have to be blocked from Microsoft and your IP domain address is being reported to the proper authorities, and multiple criminal complaints lodged against you with state and federal agencies for repeated violations of the rule of law, please get necessary help mental and counseling and medication to help you with your illegal activities, this will not be tolerated and the courst system will be notified of your harrassment, and illegal activities including the, DOJ, FBI, U.S. Postal Inspector, North Carolina State Police and Statesville, NC Local Police for your blackmailing, extortion, and attempting to obtaint money and securities under false pretences violations of federal and state laws, while this is unfortunate Immune Response BioPharma is forced to protect itself from financial terrorisim you have victimized our new company from. I demand you obey the Cease & Desist Order from 2/24/2011 and obey the rule of law and cease your criminal activities. Immune Response BioPharma will use and seek all available avenues of civil and criminal law to end your blackmailing and extortion attempts.
Sincerely,
Immune Resonse BioPharma Legal Department
Monday, June 20, 2011
David Buswell and Immune Response BioPharma
The following was the second response I received from David Buswell. I found it rather a strange response considering I did not make threats and only asked questions and expressed concern as an investor in Immune Response and Orchestra Thera (OCHTQ.PK).
This is the 2nd response from the new Immune Response and David Buswell:
From: david buswell <info@immuneresponsebiopharma.com
RE:Violations of & Desist Order 2/24/2011
You were warned not to violate the Cease & Desist Order by doing so and further actions constitute a violation and Immune Response BioPharma demands you obey and comply with the order, you have left the company with no choice but to forward your threathening emails to the authoritities for a criminal complaint against you,
for harrassment, fraud, blackmail, conspiracy, collusion, business interference, financial terrorism, your continued actions are disturbing and you should get some mental help for your problems you will be held accountable, we have no position and no intentions with regard to your garbage bankrupt defunct stock ocht/imnr it is pure trash like your emails, off to the FBI they go, you need help and are a loser who is attempting to gain financial compensation from our company through fraudulent means, blackmail, intimidation, harrassment, and repeated.
Finally get through your small brain that Immune Response BioPharma has no affiliation or connection is a brand new company while the name maybe similiar in some respects it has nothing to do with your defunct organization, and will not bow down to your blackmail demands for compensation, with you or with your bad stock investments and personal misfortunes and errors, mistakes in your life. Again, all IP has been abandoned and is Public Domain your threats are meaningless and have no merit and are a bunch of hotair, you need to get help or some medication for your issues which appear to be very serious in nature, you will only cause yourself embarrassment to your family and friends with your continued actions and possibly jail time for Interstate Commerce Fraud Federal Violations use of Mail and Wire Fraud, attempting to obtain money under false pretences, the U.S. Postal Inspectors office will be notified, your IP address will be obtained from our provider Microsoft, all emails from hospitalave Yahoo screename are being collected and turned over to the authorities for a criminal complaint and possible indictment now, you should think very seriously about obeying the rule of law, and obey the rule of law and the Cease & Desist Order. Feel free to contact any class action attorney and should they begin to harrass and make illegal unmeritied threats and demands they too willbe held accountable for a criminal complaint of fraud and business interference. Again please do not contact Immune Response BioPharma ever again.
Sincereley,
Immune Response BioPharma Legal Department
This is the 2nd response from the new Immune Response and David Buswell:
From: david buswell <info@immuneresponsebiopharma.com
RE:Violations of & Desist Order 2/24/2011
You were warned not to violate the Cease & Desist Order by doing so and further actions constitute a violation and Immune Response BioPharma demands you obey and comply with the order, you have left the company with no choice but to forward your threathening emails to the authoritities for a criminal complaint against you,
for harrassment, fraud, blackmail, conspiracy, collusion, business interference, financial terrorism, your continued actions are disturbing and you should get some mental help for your problems you will be held accountable, we have no position and no intentions with regard to your garbage bankrupt defunct stock ocht/imnr it is pure trash like your emails, off to the FBI they go, you need help and are a loser who is attempting to gain financial compensation from our company through fraudulent means, blackmail, intimidation, harrassment, and repeated.
Finally get through your small brain that Immune Response BioPharma has no affiliation or connection is a brand new company while the name maybe similiar in some respects it has nothing to do with your defunct organization, and will not bow down to your blackmail demands for compensation, with you or with your bad stock investments and personal misfortunes and errors, mistakes in your life. Again, all IP has been abandoned and is Public Domain your threats are meaningless and have no merit and are a bunch of hotair, you need to get help or some medication for your issues which appear to be very serious in nature, you will only cause yourself embarrassment to your family and friends with your continued actions and possibly jail time for Interstate Commerce Fraud Federal Violations use of Mail and Wire Fraud, attempting to obtain money under false pretences, the U.S. Postal Inspectors office will be notified, your IP address will be obtained from our provider Microsoft, all emails from hospitalave Yahoo screename are being collected and turned over to the authorities for a criminal complaint and possible indictment now, you should think very seriously about obeying the rule of law, and obey the rule of law and the Cease & Desist Order. Feel free to contact any class action attorney and should they begin to harrass and make illegal unmeritied threats and demands they too willbe held accountable for a criminal complaint of fraud and business interference. Again please do not contact Immune Response BioPharma ever again.
Sincereley,
Immune Response BioPharma Legal Department
David Buswell and Immune Response BioPharma
I wrote to David Buswell and Immune Response BioPharma in February asking if they were receiving financial support from Kevin Kimberlin and Spencer Trask. They refused to answer the question and instead sent the following:
I sent an E-mail asking if the Immune Response BioPharma company was using research from the Orchestra Therap, (OCHT) or Immune Response (IMNR) Corp as it was previously known. This is the response I received.
RE: Cease & Desist Order 2/24/2011
Thank-you for your interest, Immune Response BioPharma has no connection with defunct Orchestra Therapeutics and no legal liability with that company i see that that stock still is trading i would consult your tax preparer or accountant to assist you with your ownership of that company, unfortunately our company has no affiliation with that organization and can not offer advice or guidance on your situation. In the interest of saving lives the new company has been formed with saving lives and helping advance science at this time has no publicly traded securities and has no immediate plans to issue any securities nor has any for sale, nor any obligation to any defunct or bankrupt company nor its shareholders. Furthemore has no compensation to offer you as the company has no affiliation with you, and no plans to compensate anyone with regards to a bankrupt company. While this may not be the answer you-re seeking i would refer you to the USPTO.GOV and abandoned patents and trademarks and public domain of those IP and rights once they become legally abandoned or used after certain periods of time.
I would ask you to respect the rule of law and cease and desist from contacting, harassing, interference of business, fraud, manipulation, slander, defamation, illegal activities, written or oral communication threathening, harming, cyber attacks, physical or oral or via mail any blackmail or greenmail activities or otherwise prohibited illegal activities against Immune Response BioPharma or its employees, founders or members in any shape form or fashion will be deemed as hostile acts and reported to the proper authorities. Immune Respone BioPharma is a peaceful company only seeking to save lives and has its own pipeline of life saving drugs and will act responsibly by developing those therapeutic treatments in the of mankind. Should you continue with your course of actions it will become a criminal matter which the proper authorities will be notified, at this time Immune Response BioPharma will not pursue any legal actions but cautions you to refrain from further activities that would otherwise violate the rule of law. Mr. Reese make no mistake you will be held accountable should you continue to harrass, impede, threathen, blackmail, interfere with our business and notify the Department of Justice and the FBI should you send more harrassing emails. Please Cease & Desist as of 2/24/2011 your activities and contact with Immune Response BioPharma, should you violate this order appropriate legal action will be taken. Immune Response BioPharma will use any and all legal avenues civil and criminal to halt any violations of this order.
Sincerely, Immune Response BioPharma Legal Department
I sent an E-mail asking if the Immune Response BioPharma company was using research from the Orchestra Therap, (OCHT) or Immune Response (IMNR) Corp as it was previously known. This is the response I received.
RE: Cease & Desist Order 2/24/2011
Thank-you for your interest, Immune Response BioPharma has no connection with defunct Orchestra Therapeutics and no legal liability with that company i see that that stock still is trading i would consult your tax preparer or accountant to assist you with your ownership of that company, unfortunately our company has no affiliation with that organization and can not offer advice or guidance on your situation. In the interest of saving lives the new company has been formed with saving lives and helping advance science at this time has no publicly traded securities and has no immediate plans to issue any securities nor has any for sale, nor any obligation to any defunct or bankrupt company nor its shareholders. Furthemore has no compensation to offer you as the company has no affiliation with you, and no plans to compensate anyone with regards to a bankrupt company. While this may not be the answer you-re seeking i would refer you to the USPTO.GOV and abandoned patents and trademarks and public domain of those IP and rights once they become legally abandoned or used after certain periods of time.
I would ask you to respect the rule of law and cease and desist from contacting, harassing, interference of business, fraud, manipulation, slander, defamation, illegal activities, written or oral communication threathening, harming, cyber attacks, physical or oral or via mail any blackmail or greenmail activities or otherwise prohibited illegal activities against Immune Response BioPharma or its employees, founders or members in any shape form or fashion will be deemed as hostile acts and reported to the proper authorities. Immune Respone BioPharma is a peaceful company only seeking to save lives and has its own pipeline of life saving drugs and will act responsibly by developing those therapeutic treatments in the of mankind. Should you continue with your course of actions it will become a criminal matter which the proper authorities will be notified, at this time Immune Response BioPharma will not pursue any legal actions but cautions you to refrain from further activities that would otherwise violate the rule of law. Mr. Reese make no mistake you will be held accountable should you continue to harrass, impede, threathen, blackmail, interfere with our business and notify the Department of Justice and the FBI should you send more harrassing emails. Please Cease & Desist as of 2/24/2011 your activities and contact with Immune Response BioPharma, should you violate this order appropriate legal action will be taken. Immune Response BioPharma will use any and all legal avenues civil and criminal to halt any violations of this order.
Sincerely, Immune Response BioPharma Legal Department
Saturday, June 18, 2011
Immune Response Corporation and Orchestra Therapeutics, Inc.
The Immune Response Corporation announced on April 16, 2007 that it was changing its name to Orchestra Therapeutics, Inc. The company annunced the rebranding as an effort to reflect expanded focus on Treatment of Autoimmune Disease. The company also annouced that it was terminating its HIV clinical trials to focus fully on its autoimmune program. The company's lead immune-based therapeutic product candidate is NeuroVax(TM) for the treatment of MS.
Thursday, June 16, 2011
Immune Response Corporation
One of the early disasters for Immune Response (IMNR) later Orchestra Therapeutics (OCHTQ.PK) occurred in December of 2000. A report surfaced that the biotechnology company tried to block publication of a major AIDS study that found that the experimental treatment the company was developing failed to improve the health of patients, the scientists conducting the research said. An article by Scott Gottlieb in Vaccines and Microbicides said that "The Immune Response company of Carlsbad, California, opposed publication of the study because it did not include a subanalysis it believed showed that the treatment boosted the immune system of some patients. But despite the objections of the company, the researchers, led by James Kahn of the University of California at San Francisco, submitted their results to JAMA, which published them."
The researchers reported that the study of 2527 patients at 77 hospitals tested the vaccine marketed under the name Remune and concluded that it failed to show any advantage in survival or in slowing the progression of Aids. "In September the vaccine's manufacturer refused to provide all the study data to Dr. Kahn and his colleagues, and Dr. Kahn refused to put what the company wanted in the paper. Dr. Kahn and his colleagues felt that the information that the company wished to include was "data dredging" which investors took to be an attempt by the company to hide or manipulate the negative test results.
The bad publicity the dispute between the company and the scientists conducting their research proved very damaging to the companies reputation.
The researchers reported that the study of 2527 patients at 77 hospitals tested the vaccine marketed under the name Remune and concluded that it failed to show any advantage in survival or in slowing the progression of Aids. "In September the vaccine's manufacturer refused to provide all the study data to Dr. Kahn and his colleagues, and Dr. Kahn refused to put what the company wanted in the paper. Dr. Kahn and his colleagues felt that the information that the company wished to include was "data dredging" which investors took to be an attempt by the company to hide or manipulate the negative test results.
The bad publicity the dispute between the company and the scientists conducting their research proved very damaging to the companies reputation.
Wednesday, June 15, 2011
Immune Response BioPharma
I invested in a company called Immune Response Corporation (IMNR) many years ago after learning that my sister and a close friend had both been diagnosed with Rheumatoid arthritis. Immune Response was started in 1986 by Kevin Kimberlin and Jonas Salk the inventor of the Polio vaccine. The company was originally formed in response to the Aids epidemic and later branched out into other research such as rheumatoid arthritis. The company's main focus was on their Aids vaccine called REMUNE and IR103 which they claimed stabilized CD4+ Cell Counts In Drug-Naive HIV patients. In early 2007 the company began trails of a new drug called NeuroVax(TM) for Treatment of Multiple Sclerosis. The company invested thousands of hours of research along with millions of dollars in hopes of bringing a product to market. The company was first met on Wall Street with great enthusiasm with its connection to the renowned Joans Salk. The company entered into a partnership agreement with Pfizer and was developing the aids drug with a unit of Pfizer called Agouron Pharmaceuticals. The company's spokesperson Kathy Lane gave regular updates on the progress of the companies research and investors and sufferers of the various diseases they were researching had great hope.
Gradually hope and the stock price began to fall as the companies research trails continued to return failing results. In July 2001 shares for the stock were cut in half after Pfizer announced they were terminating a partnership to develop Remune's AIDS vaccine. Basically, observers noted that the companies research trails had been so poorly designed and administered that even what little positive results they achieved could not be trusted by the scientific community. The companies shares plunged as investors and employees of the company cut their losses and moved on.
In attempts to stay on the NASDAX the company reversed stock prices twice and changed their name to Orchestra Therapeutics (OCHT) in hopes of luring in more investors to stay afloat. The companies co-founder Kevin Kimberlin through Spencer Trask began giving operating money to the company in return for ownership of the companies intellectual property rights until the company finally filed Chapter 7.
A new company then emerged called Immune Response Biopharma led by David Buswell. This company claims that the research and intellectual property rights of the stock holders and Kevin Kimberlin were abandoned and that they have now claimed legal ownership. Immune Response Biopharma is seeking to issue an IPO using the Immune/Orchestra research. A spokesperson for Immune Response Biopharma said that what they are attempting to market and develop was essentially left in the trash.
Gradually hope and the stock price began to fall as the companies research trails continued to return failing results. In July 2001 shares for the stock were cut in half after Pfizer announced they were terminating a partnership to develop Remune's AIDS vaccine. Basically, observers noted that the companies research trails had been so poorly designed and administered that even what little positive results they achieved could not be trusted by the scientific community. The companies shares plunged as investors and employees of the company cut their losses and moved on.
In attempts to stay on the NASDAX the company reversed stock prices twice and changed their name to Orchestra Therapeutics (OCHT) in hopes of luring in more investors to stay afloat. The companies co-founder Kevin Kimberlin through Spencer Trask began giving operating money to the company in return for ownership of the companies intellectual property rights until the company finally filed Chapter 7.
A new company then emerged called Immune Response Biopharma led by David Buswell. This company claims that the research and intellectual property rights of the stock holders and Kevin Kimberlin were abandoned and that they have now claimed legal ownership. Immune Response Biopharma is seeking to issue an IPO using the Immune/Orchestra research. A spokesperson for Immune Response Biopharma said that what they are attempting to market and develop was essentially left in the trash.
Tuesday, June 14, 2011
Immune Response BioPharma and Immune Response Corporation and Orchestra Therapeutics, Inc. Kevin Kimberlin, & Spencer Trask
This blog is concerning a new company recently formed by a David Buswell called Immune Response BioPharma and this companies use of the research begun in 1988 by Kevin Kimberlin and Jonas Salk in a company called the Immune Response Corporation (IMNR) (now Orchestra Therapeutics, Inc.). This company now trades under the symbol OCHTQ.PK. David Buswell and Immune Response BioPharma are now laying claims to the research conducted by Immune Response/Orchestra saying that the research has been abandoned though stockholders in the company still hold, buy and sell stock in the compnay and have not relinquished any of their rights. Immune Response BioPharma plans on issuing stock through an IPO offering though they say that the research they are basing their company on was found in the "trash." This blog is being written by a long time stock holder in IMNR/OCHT who wishes to defend his rights as a stock holder and investor who financed the research that David Buswell and company are now trying to market. I also wish to inform others as to the history and connection of Immune Response BioPharma to Immune Response Corporation and Orchestra Therapeutics, Inc.
Subscribe to:
Posts (Atom)